Cargando…

Clinical Character of CASPR2 Autoimmune Encephalitis: A Multiple Center Retrospective Study

OBJECTIVE: To examine the clinical characteristics of autoimmune encephalitis associated with the contactin-associated protein-2 (CASPR2) antibody. MATERIALS AND METHODS: Medical records of all patients diagnosed with CASPR2 antibody-associated encephalitis were retrospectively analysed. Data regard...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Xiaoxiao, Yang, Huajun, Zhu, Fei, Wang, Qun, Shan, Wei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159154/
https://www.ncbi.nlm.nih.gov/pubmed/34054814
http://dx.doi.org/10.3389/fimmu.2021.652864
_version_ 1783700022073753600
author Qin, Xiaoxiao
Yang, Huajun
Zhu, Fei
Wang, Qun
Shan, Wei
author_facet Qin, Xiaoxiao
Yang, Huajun
Zhu, Fei
Wang, Qun
Shan, Wei
author_sort Qin, Xiaoxiao
collection PubMed
description OBJECTIVE: To examine the clinical characteristics of autoimmune encephalitis associated with the contactin-associated protein-2 (CASPR2) antibody. MATERIALS AND METHODS: Medical records of all patients diagnosed with CASPR2 antibody-associated encephalitis were retrospectively analysed. Data regarding demographic features, neurological symptoms and signs, laboratory tests, imaging results, treatments, and prognosis were collected. RESULTS: A total of 25 patients aged from 3 to 79 years old were enrolled in this study, with a median age of 43. Eight of 25 (32%) were female, and 17 of 25 (68%) were male. The median age of symptom onset was 42 years old with the course of disease from onset to hospital admission ranging from 2 days to 6 months (median was 17 days). Six patients (6/25) had fever as an onset symptom. During the course of disease, cognitive disturbance was the most common symptom, which was observed in 17 patients (17/25) in total. Eight patients (8/25) met the criteria for limbic encephalitis. Epileptic seizure occurred in six of these eight patients. Four patients (4/25) were diagnosed as Morvan syndrome. All patients were positive for anti-CASPR2 antibody in the serum (1:10–1:300). In six patients, antibodies were detected both in the blood and CSF (1:32–1:100). White blood cell (WBC) counts in the CSF were elevated in eight patients (8/25). The concentration of proteins in CSF increased in 10 patients (ranging from 480 to 1,337.6 mg/dl), decreased in seven patients (ranging from 23.2 to 130.5 mg/dl) and remained at a normal range in the other eight patients (ranging from 150 to 450 mg/dl). Abnormal electroencephalogram (EEG) activities included slow background activity and epileptic patterns. Abnormal signals in the bilateral hippocampus were detected by magnetic resonance imaging (MRI) in three patients presenting cognitive disturbance. In one patient who had limbic encephalitis, increased metabolism of bilateral basal ganglia and the mesial temporal lobe was revealed by PET-CT. Eleven of 15 patients receiving immunotherapy experienced varying degrees of improvement. Relapse occurred in four of 25 patients (4/25) after 2 months. CONCLUSION: CASPR-antibody-mediated autoimmune encephalitis is characterized by diverse clinical manifestations. The most prominent conclusion revealed by this retrospective analysis is the involvement of both central and peripheral nerve systems, as well as a lower relapse rate, a good response to immunotherapy, and favorable short-term prognosis after treatment was also demonstrated. Besides, additional work is necessary to evaluate the long-term prognosis.
format Online
Article
Text
id pubmed-8159154
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-81591542021-05-28 Clinical Character of CASPR2 Autoimmune Encephalitis: A Multiple Center Retrospective Study Qin, Xiaoxiao Yang, Huajun Zhu, Fei Wang, Qun Shan, Wei Front Immunol Immunology OBJECTIVE: To examine the clinical characteristics of autoimmune encephalitis associated with the contactin-associated protein-2 (CASPR2) antibody. MATERIALS AND METHODS: Medical records of all patients diagnosed with CASPR2 antibody-associated encephalitis were retrospectively analysed. Data regarding demographic features, neurological symptoms and signs, laboratory tests, imaging results, treatments, and prognosis were collected. RESULTS: A total of 25 patients aged from 3 to 79 years old were enrolled in this study, with a median age of 43. Eight of 25 (32%) were female, and 17 of 25 (68%) were male. The median age of symptom onset was 42 years old with the course of disease from onset to hospital admission ranging from 2 days to 6 months (median was 17 days). Six patients (6/25) had fever as an onset symptom. During the course of disease, cognitive disturbance was the most common symptom, which was observed in 17 patients (17/25) in total. Eight patients (8/25) met the criteria for limbic encephalitis. Epileptic seizure occurred in six of these eight patients. Four patients (4/25) were diagnosed as Morvan syndrome. All patients were positive for anti-CASPR2 antibody in the serum (1:10–1:300). In six patients, antibodies were detected both in the blood and CSF (1:32–1:100). White blood cell (WBC) counts in the CSF were elevated in eight patients (8/25). The concentration of proteins in CSF increased in 10 patients (ranging from 480 to 1,337.6 mg/dl), decreased in seven patients (ranging from 23.2 to 130.5 mg/dl) and remained at a normal range in the other eight patients (ranging from 150 to 450 mg/dl). Abnormal electroencephalogram (EEG) activities included slow background activity and epileptic patterns. Abnormal signals in the bilateral hippocampus were detected by magnetic resonance imaging (MRI) in three patients presenting cognitive disturbance. In one patient who had limbic encephalitis, increased metabolism of bilateral basal ganglia and the mesial temporal lobe was revealed by PET-CT. Eleven of 15 patients receiving immunotherapy experienced varying degrees of improvement. Relapse occurred in four of 25 patients (4/25) after 2 months. CONCLUSION: CASPR-antibody-mediated autoimmune encephalitis is characterized by diverse clinical manifestations. The most prominent conclusion revealed by this retrospective analysis is the involvement of both central and peripheral nerve systems, as well as a lower relapse rate, a good response to immunotherapy, and favorable short-term prognosis after treatment was also demonstrated. Besides, additional work is necessary to evaluate the long-term prognosis. Frontiers Media S.A. 2021-05-13 /pmc/articles/PMC8159154/ /pubmed/34054814 http://dx.doi.org/10.3389/fimmu.2021.652864 Text en Copyright © 2021 Qin, Yang, Zhu, Wang and Shan https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Qin, Xiaoxiao
Yang, Huajun
Zhu, Fei
Wang, Qun
Shan, Wei
Clinical Character of CASPR2 Autoimmune Encephalitis: A Multiple Center Retrospective Study
title Clinical Character of CASPR2 Autoimmune Encephalitis: A Multiple Center Retrospective Study
title_full Clinical Character of CASPR2 Autoimmune Encephalitis: A Multiple Center Retrospective Study
title_fullStr Clinical Character of CASPR2 Autoimmune Encephalitis: A Multiple Center Retrospective Study
title_full_unstemmed Clinical Character of CASPR2 Autoimmune Encephalitis: A Multiple Center Retrospective Study
title_short Clinical Character of CASPR2 Autoimmune Encephalitis: A Multiple Center Retrospective Study
title_sort clinical character of caspr2 autoimmune encephalitis: a multiple center retrospective study
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8159154/
https://www.ncbi.nlm.nih.gov/pubmed/34054814
http://dx.doi.org/10.3389/fimmu.2021.652864
work_keys_str_mv AT qinxiaoxiao clinicalcharacterofcaspr2autoimmuneencephalitisamultiplecenterretrospectivestudy
AT yanghuajun clinicalcharacterofcaspr2autoimmuneencephalitisamultiplecenterretrospectivestudy
AT zhufei clinicalcharacterofcaspr2autoimmuneencephalitisamultiplecenterretrospectivestudy
AT wangqun clinicalcharacterofcaspr2autoimmuneencephalitisamultiplecenterretrospectivestudy
AT shanwei clinicalcharacterofcaspr2autoimmuneencephalitisamultiplecenterretrospectivestudy